Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Gum Arabic Company (GAC) is the primary state-linked enterprise in Sudan responsible for the processing and global export of gum arabic, a natural exudate from Acacia trees. As Sudan provides approximately 70% of the world's supply, GAC is a critical player in the global supply chain for the pharmaceutical, food, and cosmetic industries. The company's products, primarily Acacia Senegal (Hashab) and Acacia Seyal (Talha), serve as essential pharmaceutical excipients used for tablet binding, emulsification, and encapsulation. Beyond its role as an ingredient supplier, GAC is involved in the distribution of high-purity grades for medical applications, including its use as a prebiotic fiber and its studied benefits in reducing urea levels in patients with chronic kidney disease. Despite regional challenges, the company remains the central authority for quality control and standardization of Sudanese gum arabic exports.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sudani Arabic Gum.